Stock PHG PHILIPS NV
Add to a list
To use this feature you must be a member
Log inSign up

Financials Philips NV Nyse

Equities

PHG

US5004723038

Advanced Medical Equipment & Technology

Delayed Nyse
Other stock markets
 03:50:36 2024-05-02 pm EDT 		5-day change 1st Jan Change
26.56 USD -0.77% Intraday chart for Philips NV +28.19% +13.84%
02:08pm PHILIPS NV : DZ Bank reiterates its Neutral rating ZD
01:03pm Moody's Affirms Royal Philips' Rating, Upgrades Outlook on Enhanced Performance MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 38,967 39,817 28,161 12,398 19,314 22,625 - -
Enterprise Value (EV) 1 42,989 43,525 32,837 18,485 25,131 27,521 27,359 26,465
P/E ratio 33.5 x 33.9 x 8.98 x -7.69 x -41.3 x 51.8 x 22.3 x 17.9 x
Yield 1.95% 1.94% 2.59% 6.07% 4.03% 3.45% 3.59% 3.76%
Capitalization / Revenue 2 x 2.04 x 1.64 x 0.7 x 1.06 x 1.21 x 1.15 x 1.1 x
EV / Revenue 2.21 x 2.23 x 1.91 x 1.04 x 1.38 x 1.47 x 1.39 x 1.28 x
EV / EBITDA 11.9 x 11.7 x 11 x 8.02 x 8.83 x 8.87 x 8.03 x 7.23 x
EV / FCF 40.8 x 23.5 x 36.5 x -19.2 x 15.9 x 21.5 x 25.7 x 16.2 x
FCF Yield 2.45% 4.26% 2.74% -5.2% 6.3% 4.65% 3.89% 6.17%
Price to Book 3.08 x 3.34 x 1.97 x 0.93 x 1.61 x 1.95 x 1.87 x 1.79 x
Nbr of stocks (in thousands) 954,336 950,090 897,866 924,889 915,987 904,257 - -
Reference price 2 40.83 41.91 31.36 13.41 21.08 25.02 25.02 25.02
Announcement Date 1/28/20 1/25/21 1/24/22 1/30/23 1/29/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 19,482 19,535 17,156 17,827 18,169 18,681 19,668 20,635
EBITDA 1 3,615 3,709 2,985 2,305 2,845 3,102 3,406 3,661
EBIT 1 2,563 2,570 2,054 1,318 1,921 2,139 2,357 2,606
Operating Margin 13.16% 13.16% 11.97% 7.39% 10.57% 11.45% 11.98% 12.63%
Earnings before Tax (EBT) 1 1,529 1,490 509 -1,731 -526 385 1,590 1,934
Net income 1 1,167 1,187 3,319 -1,608 -466 565.3 1,164 1,411
Net margin 5.99% 6.08% 19.35% -9.02% -2.56% 3.03% 5.92% 6.84%
EPS 2 1.220 1.235 3.494 -1.742 -0.5100 0.4826 1.122 1.395
Free Cash Flow 1 1,053 1,852 900 -961 1,582 1,279 1,065 1,633
FCF margin 5.4% 9.48% 5.25% -5.39% 8.71% 6.85% 5.41% 7.92%
FCF Conversion (EBITDA) 29.13% 49.93% 30.15% - 55.61% 41.22% 31.26% 44.61%
FCF Conversion (Net income) 90.23% 156.02% 27.12% - - 226.22% 91.44% 115.74%
Dividend per Share 2 0.7975 0.8137 0.8137 0.8137 0.8500 0.8624 0.8979 0.9406
Announcement Date 1/28/20 1/25/21 1/24/22 1/30/23 1/29/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 8,554 8,057 4,156 4,944 3,918 4,177 8,095 4,310 5,422 4,167 4,470 4,471 5,062 4,138 4,509 4,653 5,471 -
EBITDA - - - - - - - - - - - - 896 - 673.3 725.2 1,065 -
EBIT 662 - 512 - 243 216 459 209 651 359 453 457 653 - 475 582.6 837.3 -
Operating Margin 7.74% - 12.32% - 6.2% 5.17% 5.67% 4.85% 12.01% 8.62% 10.13% 10.22% 12.9% - 10.54% 12.52% 15.3% -
Earnings before Tax (EBT) - - - - - - - - 7 - - 130 - - - - - -
Net income 1 246 - 2,973 157 -151 -22 -173 -1,330 -106 - 72 88 39 -999 711.7 247.2 217.3 -
Net margin 2.88% - 71.54% 3.18% -3.85% -0.53% -2.14% -30.86% -1.95% - 1.61% 1.97% 0.77% -24.14% 15.78% 5.31% 3.97% -
EPS 2 - - 3.101 0.1723 -0.1627 -0.0191 - -1.436 -0.1149 - 0.0800 0.0900 0.0400 -1.100 0.7874 0.2742 0.2359 -
Dividend per Share 2 - - - 0.8137 - - - - 0.8137 - - - - - - - - -
Announcement Date 7/20/20 7/26/21 10/18/21 1/24/22 4/25/22 7/25/22 7/25/22 10/24/22 1/30/23 4/24/23 7/24/23 10/23/23 1/29/24 4/29/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,022 3,708 4,676 6,087 5,817 4,896 4,734 3,841
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.113 x 0.9997 x 1.566 x 2.641 x 2.045 x 1.578 x 1.39 x 1.049 x
Free Cash Flow 1 1,053 1,852 900 -961 1,582 1,279 1,065 1,633
ROE (net income / shareholders' equity) 14.9% 9.7% 25.3% 6.1% 9.08% 11.4% 12.8% 13.6%
ROA (Net income/ Total Assets) 6.94% 6.63% 5.1% 2.74% 3.82% 2.93% 3.68% 4.66%
Assets 1 16,817 17,906 65,043 -58,658 -12,197 19,279 31,648 30,266
Book Value Per Share 2 13.30 12.50 15.90 14.40 13.10 12.90 13.40 14.00
Cash Flow per Share 2 2.090 2.900 1.710 -0.1900 2.330 2.030 2.110 2.640
Capex 1 978 924 729 788 554 953 991 1,043
Capex / Sales 5.02% 4.73% 4.25% 4.42% 3.05% 5.1% 5.04% 5.06%
Announcement Date 1/28/20 1/25/21 1/24/22 1/30/23 1/29/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Philips NV

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
25.25 EUR
Average target price
24.02 EUR
Spread / Average Target
-4.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.42% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.31% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.80% 132B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.34% 106B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-2.66% 62.09B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.88B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+11.24% 50.8B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.42% 40.64B
RESMED, INC. Stock ResMed, Inc.
+26.27% 31.59B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. PHIA Stock
  4. PHG Stock
  5. Financials Philips NV